MedPath

Dexamethasone Iontophoretic Patch for the Treatment of Pain Associated With Lateral Epicondylitis

Phase 2
Completed
Conditions
(Tennis Elbow)
Lateral Epicondylitis
Interventions
Registration Number
NCT00794976
Lead Sponsor
Travanti Pharma Inc.
Brief Summary

The objective of this study is to determine the safety and efficacy of a dexamethasone iontophoretic transdermal patch for the treatment of pain associated with lateral epicondylitis (tennis elbow).

Detailed Description

Detailed Description:

This trial is a randomized, double-blind, placebo-controlled, parallel-group trial in subjects diagnosed with lateral epicondylitis (tennis elbow). Subjects entered into the trial will be assigned to one of four treatment groups. The total duration is up to 13 days of trial participation.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
216
Inclusion Criteria
  • Subjects with onset of lateral epicondylitis symptoms no more than 12 weeks prior to study entry
  • Female patients of childbearing potential must agree to use a medically accepted form of birth control.
Exclusion Criteria
  • Subjects with other medical conditions/injuries of the elbow that would account for pain in the area
  • Subjects who would require continuation of current pain medications during treatment
  • Must not have received a prior corticosteroid injection for lateral epicondylitis in the affected arm

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1Dexamethasone Iontophoretic Patch (low dose)Dexamethasone Iontophoretic Patch (low dose)
2Dexamethasone Iontophoretic Patch (high dose)Dexamethasone Iontophoretic Patch (high dose)
3Dexamethasone Passive PatchDexamethasone Passive Patch
4Placebo PatchPlacebo Patch
Primary Outcome Measures
NameTimeMethod
Pain severity assessed by VAS (Visual Analog Scale)baseline to completion/termination
Secondary Outcome Measures
NameTimeMethod
Safetyup to 13 days
© Copyright 2025. All Rights Reserved by MedPath